Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation
© 2023. The Author(s), under exclusive licence to Springer Nature B.V..
Nucleosides and purine nucleotides serve as transmitter and modulator agents that extend their functions beyond the cell. In this context, purinergic signaling plays a crucial role in regulating energy homeostasis and modulating metabolic alterations in tumor cells. Therefore, it is essential to consider the pharmacological targeting of purinergic receptors (PUR), which encompass the expression and inhibition of P1 receptors (metabotropic adenosine receptors) as well as P2 receptors (extracellular ATP/ADP) comprising P2X and P2Y receptors. Thus, the pharmacological interaction between inhibitors (such as RNA, monoclonal antibodies, and small molecules) and PUR represents a key aspect in facilitating the development of therapeutic interventions. Moreover, this review explores recent advancements in pharmacological inhibitors and the regulation of innate and adaptive immunity of PUR, specifically in relation to immunological and inflammatory responses. These responses encompass the release of pro-inflammatory cytokines (PIC), the production of reactive oxygen and nitrogen species (ROS and RNS), the regulation of T cells, and the activation of inflammasomes in all human leukocytes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
Purinergic signalling - (2023) vom: 16. Okt. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kiaie, Seyed Hossein [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ATP |
|---|
| Anmerkungen: |
Date Revised 16.10.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1007/s11302-023-09966-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363365621 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363365621 | ||
| 003 | DE-627 | ||
| 005 | 20231226093206.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11302-023-09966-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363365621 | ||
| 035 | |a (NLM)37843749 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kiaie, Seyed Hossein |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological interaction and immune response of purinergic receptors in therapeutic modulation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Nature B.V. | ||
| 520 | |a Nucleosides and purine nucleotides serve as transmitter and modulator agents that extend their functions beyond the cell. In this context, purinergic signaling plays a crucial role in regulating energy homeostasis and modulating metabolic alterations in tumor cells. Therefore, it is essential to consider the pharmacological targeting of purinergic receptors (PUR), which encompass the expression and inhibition of P1 receptors (metabotropic adenosine receptors) as well as P2 receptors (extracellular ATP/ADP) comprising P2X and P2Y receptors. Thus, the pharmacological interaction between inhibitors (such as RNA, monoclonal antibodies, and small molecules) and PUR represents a key aspect in facilitating the development of therapeutic interventions. Moreover, this review explores recent advancements in pharmacological inhibitors and the regulation of innate and adaptive immunity of PUR, specifically in relation to immunological and inflammatory responses. These responses encompass the release of pro-inflammatory cytokines (PIC), the production of reactive oxygen and nitrogen species (ROS and RNS), the regulation of T cells, and the activation of inflammasomes in all human leukocytes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ATP | |
| 650 | 4 | |a Adenosine | |
| 650 | 4 | |a Immune response | |
| 650 | 4 | |a Pharmacology | |
| 650 | 4 | |a Purinergic receptor | |
| 700 | 1 | |a Hatami, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Nasr, Mohammad Sadegh |e verfasserin |4 aut | |
| 700 | 1 | |a Pazooki, Pouya |e verfasserin |4 aut | |
| 700 | 1 | |a Hemmati, Salar |e verfasserin |4 aut | |
| 700 | 1 | |a Baradaran, Behzad |e verfasserin |4 aut | |
| 700 | 1 | |a Valizadeh, Hadi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Purinergic signalling |d 2004 |g (2023) vom: 16. Okt. |w (DE-627)NLM160620074 |x 1573-9546 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:16 |g month:10 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11302-023-09966-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 16 |c 10 | ||